Equities analysts expect The Medicines Company (NASDAQ:MDCO) to post earnings of ($0.63) per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for The Medicines’ earnings, with the highest EPS estimate coming in at ($0.45) and the lowest estimate coming in at ($0.94). The Medicines reported earnings per share of ($2.19) during the same quarter last year, which suggests a positive year over year growth rate of 71.2%. The business is expected to report its next earnings results on Wednesday, February 20th.
On average, analysts expect that The Medicines will report full-year earnings of ($2.41) per share for the current fiscal year, with EPS estimates ranging from ($2.67) to ($1.91). For the next year, analysts forecast that the business will post earnings of ($2.22) per share, with EPS estimates ranging from ($3.15) to ($1.43). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover The Medicines.
The Medicines (NASDAQ:MDCO) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.13). The Medicines had a negative return on equity of 1,477.75% and a negative net margin of 668.93%. The firm had revenue of ($3.30) million for the quarter, compared to analyst estimates of $1.88 million. During the same quarter in the prior year, the firm earned ($1.19) earnings per share. The firm’s revenue for the quarter was down 141.8% on a year-over-year basis.
A number of analysts recently issued reports on MDCO shares. Cowen set a $46.00 price objective on shares of The Medicines and gave the stock a “buy” rating in a report on Sunday, November 11th. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a report on Friday, December 7th. BidaskClub upgraded shares of The Medicines from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 22nd. Oppenheimer set a $50.00 target price on shares of The Medicines and gave the stock a “buy” rating in a research note on Friday, November 9th. Finally, ValuEngine downgraded shares of The Medicines from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $49.67.
NASDAQ MDCO traded up $0.07 during trading hours on Wednesday, reaching $19.81. 197,093 shares of the company were exchanged, compared to its average volume of 1,533,450. The Medicines has a 1 year low of $16.69 and a 1 year high of $41.57. The company has a debt-to-equity ratio of 31.23, a quick ratio of 2.40 and a current ratio of 2.41. The company has a market capitalization of $1.46 billion, a PE ratio of -2.36 and a beta of 1.06.
In other news, Director Alexander J. Denner acquired 819,000 shares of the business’s stock in a transaction dated Friday, December 14th. The stock was bought at an average cost of $20.26 per share, for a total transaction of $16,592,940.00. Following the completion of the transaction, the director now owns 10,429 shares of the company’s stock, valued at $211,291.54. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark Timney acquired 2,926 shares of the business’s stock in a transaction dated Friday, December 21st. The stock was purchased at an average price of $17.90 per share, with a total value of $52,375.40. Following the completion of the transaction, the chief executive officer now directly owns 29,789 shares of the company’s stock, valued at approximately $533,223.10. The disclosure for this purchase can be found here. Insiders bought 1,052,589 shares of company stock valued at $20,865,236 in the last quarter. Corporate insiders own 10.29% of the company’s stock.
Several large investors have recently added to or reduced their stakes in MDCO. Riverhead Capital Management LLC grew its position in shares of The Medicines by 32.2% in the 3rd quarter. Riverhead Capital Management LLC now owns 12,306 shares of the company’s stock worth $368,000 after buying an additional 3,000 shares during the period. Quantbot Technologies LP purchased a new stake in shares of The Medicines in the 3rd quarter worth about $369,000. Stevens Capital Management LP purchased a new stake in shares of The Medicines in the 3rd quarter worth about $395,000. State of Alaska Department of Revenue grew its position in shares of The Medicines by 3.2% in the 4th quarter. State of Alaska Department of Revenue now owns 22,020 shares of the company’s stock worth $421,000 after buying an additional 681 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of The Medicines by 144.4% in the 2nd quarter. SG Americas Securities LLC now owns 12,462 shares of the company’s stock worth $457,000 after buying an additional 7,362 shares during the period.
About The Medicines
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Featured Story: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.